HackerTrans
TopNewTrendsCommentsPastAskShowJobs

calculito

no profile record

Submissions

[untitled]

1 points·by calculito·w zeszłym roku·0 comments

Pharma Giants, Crypto Profits: How Ozempic Could Redefine Corporate Investment

ion-oaie.medium.com
2 points·by calculito·2 lata temu·1 comments

Ask HN: RAG and unstructured data from several docs

6 points·by calculito·2 lata temu·3 comments

comments

calculito
·w zeszłym roku·discuss
[dead]
calculito
·2 lata temu·discuss
With the booming demand for weight-loss drugs like Ozempic, pharmaceutical giants are poised for unprecedented profits in 2025. Beyond traditional reinvestments, these companies are reportedly turning to cryptocurrencies like EOS and BLOK, seeking liquidity and growth through innovative financial strategies.

The approach is bold yet calculated. Pharma corporations plan to invest in niche cryptocurrencies, leveraging their market influence to boost interest and value. Once prices rise, they’ll liquidate a significant portion—up to 60%—to fund operations, R&D, and expansion. To maintain investor trust and market stability, they might reinvest in the same tokens, creating what some are calling a “Crypto Investment Loop.”

Cryptocurrencies offer unique advantages: round-the-clock trading, unparalleled liquidity, and the ability to generate rapid short-term gains. This model positions crypto as a critical tool for corporate finance, challenging traditional methods like bonds and equity.

However, this strategy is not without risks. Critics warn of potential market manipulation and regulatory scrutiny, while retail investors face the volatility of speculative markets. Transparency will be vital for pharma companies to avoid ethical pitfalls.

If successful, this approach could redefine corporate investment across industries, demonstrating how established sectors can use blockchain technologies to generate capital and foster innovation. By combining the stability of healthcare with the dynamism of crypto, 2025 might mark a turning point in the integration of decentralized finance and corporate growth.
calculito
·2 lata temu·discuss
Thanks for the comments. Regarding re-chunking: I assume the models, the strategies, the dependencies are continuously checken, improved and adapted. I would assume also a re-chunking should be necessary. Not every day of course, but how I can assess the quality of my chunking? Running in parallel benchmarks on two different chunking strategies? Thats means I would need to do double work, creating and using continuously two different chunk systems. Any ideas how to evaluate the quality and performance of my chunking strategy?
calculito
·2 lata temu·discuss
ok, it's easy for you to understand. For some other people, me for example, not that easy. The question is also, how is is possible. So, I don't expect a detailed explanation or a step-by-step howTo but do you have any hints?
calculito
·2 lata temu·discuss
Depends of what you want to do!? Just for testing most of the 7B model are a good compromise between quality and performance (speak execution time)
calculito
·2 lata temu·discuss
I assume the question is rather which LLM can cover most of the tasks while delivering decent quality. I would prefer an architecture using different LLM for different tasks rather like 'specialists' instead of simple 'agents'. I used to take the main task and divide it in smaller tasks and see what can I use to solve the problem. Sometimes rule-based approaches can be already enough for a sub-task and LLM would be not only overkill but also more difficult to implement and maintain.